H.C. Wainwright lowered the firm’s price target on MacroGenics to $12 from $14 and keeps a Buy rating on the shares post the Q3 report. The analyst believes MacroGenics’ existing balance sheet resources should provide for an operational runway into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MGNX:
